Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: ...

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $785.09, a high estimate of $1070.00, and a low estimate of $715.00. This current ...

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis ...

The news came as RBC Capital analyst Luca Issi initiated coverage on Argenx with an outperform rating and 850 price target, saying that doctor checks point to accelerating uptake of Vyvgart, according ...